T. Rowe Price Investment Management, Inc. - REATA PHARMACEUTICALS INC ownership

REATA PHARMACEUTICALS INC's ticker is RETA and the CUSIP is 75615P103. A total of 161 filers reported holding REATA PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.58 and the average weighting 0.2%.

Quarter-by-quarter ownership
T. Rowe Price Investment Management, Inc. ownership history of REATA PHARMACEUTICALS INC
ValueSharesWeighting
Q4 2022$18,054
-99.8%
475,222
+0.0%
0.01%
+40.0%
Q3 2022$11,939,000475,0870.01%
Other shareholders
REATA PHARMACEUTICALS INC shareholders Q3 2022
NameSharesValueWeighting ↓
CPMG Inc 2,896,901$291,457,00032.14%
PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE 46,646$4,693,0005.31%
Ikarian Capital, LLC 471,400$47,423,0003.34%
Duquesne Family Office 695,033$69,927,0002.27%
Camber Capital Management LP 685,000$68,918,0002.12%
LBJ Family Wealth Advisors, Ltd. 30,359$3,054,0001.82%
MADDEN SECURITIES Corp 33,127$3,333,0001.80%
Biondo Investment Advisors, LLC 104,120$10,475,0001.80%
Tolleson Wealth Management, Inc. 60,750$6,112,0001.73%
Keel Point, LLC 97,074$9,767,0001.26%
View complete list of REATA PHARMACEUTICALS INC shareholders